Figure 1S. Study participants disposition and missing data.

710 AIRD patients vaccinated with 2 doses of BNT162b2 were recruited:
- 471 from TLVMC
- 162 from Carmel MC
- 77 from Hadassah MC
125 non-AIRD controls vaccinated with 2 doses of BNT162b2 were recruited:
- 38 from TLVMC
- 62 from Carmel MC
- 25 from Hadassah MC

24 AIRD patients (3 from TLVMC, 21 from CMC) and 5 non-AIRD controls (from C MC) were excluded due to lack of serology test result until study closure

686 AIRD patients
121 controls
Had a serology test result and were included in the primary endpoint analysis.
All patients had demographic and medication data.

Influenza vaccine: data were not reported for 13 controls from CMC and for 13 AIRD patients (7 from TLVMC, 4 from CMC and 2 from HMC).

Influenza vaccine date: data were not available for 44 out of 89 controls, and 198 out of 542 AIRD patients that were vaccinated.

Rituximab dose: data were not available for 2 out of 86 patients treated with rituximab: 1 from TLVMC, and 1 from HMC

Disease activity scores:
- RA-CDAI: Pre-vaccine: data were available for 190 out of 263 pts
  Post-vaccine: data were available for 197 out of 263 pts
- RA-SDAI: Pre-vaccine: data were available for 177 out of 263 pts
  Post-vaccine: data were available for 178 out of 263 pts
- RA-DAS28-CRP: Pre and post-vaccine: data were available for 176 out of 263 pts
- PsA-CDAI: Pre-vaccine: data were available for 124 out of 165 pts
  Post-vaccine: data were available for 132 out of 165 pts
- PsA-DAPSA: Pre and post-vaccine: data were available for 125 out of 165 pts
- PsA-PASI: Pre-vaccine: data were available for 138 out of 165 pts
  Post-vaccine: data were available for 142 out of 165 pts
- ASSpA-ASDAS: Pre-vaccine: data were available for 48 out of 68 pts
  Post-vaccine: data were available for 52 out of 68 pts
- ASSpA-BASDAI: Pre-vaccine: data were available for 52 out of 68 pts
  Post-vaccine: data were available for 58 out of 68 pts
- SLE-SLEDAI: Pre-vaccine: data were available for 94 out of 101 pts
  Post-vaccine: data were available for 87 out of 101 pts
- Vasculitis-PGA: Pre-vaccine: data were available for 66 out of 70 pts
  Post-vaccine: data were available for 64 out of 70 pts
- Vasculitis-PHS: Pre and post-vaccine data were available for 64 out of 70 pts
- iM-PGA: Pre-vaccine: data were available for all pts
  Post-vaccine: data were available for 17 out of 19 pts
- iM-PHS: Pre-vaccine: data were available for 18 out of 19 pts
  Post-vaccine: data were available for 17 out of 19 pts

Adverse events after the 1st dose of vaccine: data were not reported for 13 AIRD patients (6 from TLVMC and 7 from CMC).

Adverse events after the 2nd dose of vaccine: data were not reported for 16 AIRD patients (7 from TLVMC and 9 from CMC).
Legend: AIIRD, autoimmune inflammatory rheumatic diseases; TLVMC, Tel-Aviv Medical Center; MC, medical center; CMC, Carmel Medical Center; HMC, Hadassah Medical Center; RA, rheumatoid arthritis; CDAI, clinical disease activity index; SDAI, simplified disease activity index; DAS28-CRP, disease activity score28-CRP; PsA, psoriatic arthritis; DAPSA, disease activity psoriatic arthritis; PASI, psoriasis area severity index; AxSpA, axial spondyloarthritis; ASDAS, ankylosing spondylitis disease activity score; BASDAI, Bath ankylosing spondylitis disease activity index; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; PGA, patient global assessment; PhGA, physician global assessment; IIM, idiopathic inflammatory myositis.